Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
Returns on capital
Hemab Therapeutics Holdings, Inc. Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
36.2%
avg 36.2%
ROIC
-37.8%
avg -37.8%
ROA
-32.8%
avg -32.8%
Analysis
ROE is currently the strongest return metric at 36.2% versus its period average of 36.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Benny Sorensen | President, CEO & Director | USD 819.67K | 52 | — | — |
Mads Nikolaj Behrndt-Eriksen | CFO & GM | USD 689.14K | 43 | — | — |
Catherine Madigan | Chief Medical Officer | USD 640.56K | 54 | — | — |
Karen Weisbach | Chief People & Culture Officer | — | — | — | — |
Cecile Bonvoisin | Senior Vice President of CMC & Manufacturing | — | — | — | — |
Ananthram Sreenivasa Murthy | Chief Operating Officer | — | 48 | — | — |
Tara O'Meara | Senior Vice President of Development Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does Hemab Therapeutics Holdings, Inc. Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about COAG's management, answered from reported figures.
Who manages COAG?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) lists 7 active executives. The top listed executive is Karen Weisbach, Chief People & Culture Officer.
Are COAG insiders buying or selling?
Recent insider activity shows net buying of $1.29M.
Continue the stock analysis
Jump to another research area for this company.